Skip to main content

A comparison of two probiotic strains of bifidobacteria in premature infants.

  • 2013-12
  • The Journal of Pediatrics 163(6)
    • M. Underwood
    • K. Kalanetra
    • Nicholas A. Bokulich
    • Zachery T Lewis
    • M. Mirmiran
    • D. Tancredi
    • D. Mills

Abstract

Objective: To determine the impact of 2 probiotic bifidobacteria on the fecal microbiota of premature infants fed either human milk or formula.

Study design: In the first of two phase 1 clinical trials, 12 premature infants receiving formula feedings were assigned randomly to receive either Bifidobacterium longum ssp infantis or Bifidobacterium animalis ssp lactis in increasing doses during a 5-week period. In the second, 9 premature infants receiving their mother's milk received each of the two bifidobacteria for 2 weeks separated by a 1-week washout period. Serial stool specimens from each infant were analyzed by terminal restriction fragment-length polymorphism and quantitative polymerase chain reaction for bacterial composition.

Results: Among the formula-fed infants, there was a greater increase in fecal bifidobacteria among infants receiving B infantis (Binf) than those receiving B lactis (Blac). This difference was most marked at a dose of 1.4 × 10(9) colony-forming units twice daily (P < .05). Bacterial diversity improved over dose/time in those infants receiving Binf. Among the human milk-fed infants, greater increases in fecal bifidobacteria and decreases in γ-Proteobacteria followed the administration of Binf than Blac. The B longum group (which includes Binf but not Blac) was the dominant bifidobacteria among the human milk-fed infants, regardless of the probiotic administered.

Conclusions: Binf was more effective at colonizing the fecal microbiota than Blac in both formula-fed and human milk-fed premature infants. The combination of human milk plus Binf resulted in the greatest fecal levels of bifidobacteria.

Trial registration: ClinicalTrials.gov NCT00810160.

Keywords: B infantis; B lactis; Bac-TRFLP; Bacilli-specific terminal restriction fragment-length polymorphism; Bif-TRFLP; Bifidobacteria-specific terminal restriction fragment-length polymorphism; Binf; Blac; Colony-forming units; F+Binf; F+Blac; Formula plus Binf; Formula plus Blac; H+Binf; H+Blac; HMO; Human milk oligosaccharides; Human milk plus Binf; Human milk plus Blac; NEC; Necrotizing enterocolitis; PBS; PCoA; Phosphate-buffered saline; Principal coordinate analysis; Quantitative polymerase chain reaction; Ribosomal RNA; TRFLP; Terminal restriction fragment-length polymorphism; UC Davis; University of California, Davis; WO; Washout; cfu; qPCR; rRNA.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium infantis BI02Improved Bacterial DiversityBeneficial
Moderate
Bifidobacterium infantis BI02Increased Fecal Bifidobacteria LevelsBeneficial
Large
Bifidobacterium infantis BI02Reduced γ-Proteobacteria Levels in Human Milk-Fed InfantsBeneficial
Moderate
Bifidobacterium infantis SD-6720Improved Bacterial DiversityBeneficial
Moderate
Bifidobacterium infantis SD-6720Increased Fecal Bifidobacteria LevelsBeneficial
Large
Bifidobacterium infantis SD-6720Reduced Gamma ProteobacteriaBeneficial
Moderate
Bifidobacterium infantis VPro 53Improved Bacterial DiversityBeneficial
Moderate
Bifidobacterium infantis VPro 53Increased Fecal Bifidobacteria LevelsBeneficial
Large
Bifidobacterium infantis VPro 53Reduced Gamma ProteobacteriaBeneficial
Moderate
Bifidobacterium lactis BLA80Increased Fecal Bifidobacteria LevelsBeneficial
Large
Bifidobacterium lactis BLA80Reduced Gamma ProteobacteriaBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.